A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Otsuka America Pharmaceutical
• Treatments: Antidepressive Agents; Aripiprazole

Criteria

Inclusion Criteria:

• Men and women, 18-65 years old

• Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.

• Treatment history of an inadequate response to at least one and no more than three antidepressants.